DHEA turns up in pharmacies, on supplement shelves and in conversations about low desire, often with big promises attached. The guidance is more careful, and it treats the tablet and the vaginal form very differently.
DHEA
DHEA is a hormone your body turns into other hormones, testosterone among them. As a vaginal treatment, called prasterone, it has a place in NICE's guideline. As a tablet, the British Menopause Society says the research is not there yet.
The words and the guidance
- English
- DHEA (dehydroepiandrosterone)
- Urdu
- DHEA
- Roman Urdu
- DHEA
- NICE NG23 says doctors in England can consider vaginal prasterone, a DHEA treatment used in the vagina, for genitourinary symptoms of menopause when vaginal estrogen, or non-hormonal moisturisers or lubricants, have not worked or have not suited (1.5.10).
- The British Menopause Society says oral DHEA is used more than testosterone in some countries, but that further research is needed before it can be recommended, because trials have not definitively shown a benefit for sexual function in women whose adrenal glands work normally.
- The Pakistan Menopause Society's 2026 recommendations name prasterone among the hormones used in vaginal treatments (section 5.5). Oral DHEA appears only in the society's Table 10, as a product sold in Pakistan.
What it is
DHEA is short for dehydroepiandrosterone, a hormone the body makes and converts into other hormones. The British Menopause Society's guidance on testosterone notes that DHEA is turned into testosterone in the brain, which is one reason it comes up in discussions about desire.
It is used in menopause care in two quite different ways:
- As a vaginal treatment, under the name prasterone. The Pakistan Menopause Society lists prasterone among the hormones used in vaginal treatments (section 5.5), and NICE NG23 includes it in its recommendations for genitourinary symptoms.
- As a tablet, swallowed. This is the form the British Menopause Society says needs more research.
Which one someone means when they say DHEA makes all the difference to what the guidance says about it.
What the guidelines say about treatment
Vaginal prasterone
Genitourinary syndrome of menopause, or GSM, is the medical name for the vaginal, vulval and bladder changes that the Pakistan Menopause Society links to falling estrogen: dryness, burning, pain with sex, urgency and repeated urine infections among them (section 1.5.2 and Table 1).
NICE NG23 sets out an order for these symptoms. It recommends offering vaginal estrogen (1.5.5), and says moisturisers and lubricants without hormones can be used alongside it or instead of it (1.5.8 and 1.5.9). Vaginal prasterone comes after those: NICE says it can be considered if vaginal estrogen, or the non-hormonal moisturisers and lubricants, have not worked or have not suited (1.5.10).
The British Menopause Society's statement on GSM also gives both options. For women who can use hormones, it calls replacing the missing hormone the logical approach, and it says moisturisers have been shown to relieve dryness as well as vaginal estrogen.
Oral DHEA
The British Menopause Society's guidance on testosterone says oral DHEA is more commonly used than testosterone in some countries. It then says further research is needed before it can be recommended, because clinical trials and meta-analyses have not definitively proven a benefit for sexual function in women with normal adrenal function.
NICE NG23 does not mention oral DHEA. It does have a general line about hormone products that are not regulated: "Explain to people with menopause-associated symptoms that the efficacy and safety of unregulated hormone preparations are unknown." (1.4.5)
For low libido, the treatment the guidance discusses is testosterone, considered after HRT: NICE says testosterone can be considered for low sexual desire if HRT alone has not helped (1.5.25). More on that in testosterone therapy for women.
Available in Pakistan?
Oral DHEA is sold in Pakistan, and the Pakistan Menopause Society's 2026 Table 10 lists it among the products available there. No vaginal prasterone product is listed.
When to see a doctor
If vaginal dryness, pain with sex or low desire are affecting your life or your marriage, that is reason enough to see a doctor. These are among the symptoms the Pakistan Menopause Society says many women may not mention unless they are asked respectfully and in private, so you may have to raise them yourself.
Before starting DHEA in any form, bought or prescribed, talk to a doctor. It is a hormone, and whether it suits you depends on your history and anything else you take. If a clinic or a shop offers it to you, it is fair to ask which form it is, what it is meant to treat, and what the evidence says.
Questions to ask your doctor
- Is DHEA an option for my symptoms, and what is the evidence for it?
- Is the DHEA I have been offered a tablet or a vaginal treatment, and why that one?
- If my main problem is vaginal dryness or pain with sex, what do the guidelines suggest trying first?
- Could DHEA interact with anything else I take, or with my medical history?
Faith and family
Desire and comfort in marriage matter, and they are among the hardest things to raise with a doctor, or at home. Women ask how to talk about it with a husband, and what their faith says about it. That second question belongs with a qualified scholar you trust.
Track it
- Roshara's symptom score rates 27 symptoms in a few minutes, with no account. The total is something to take to your appointment. Take the symptom score
- Where am I? names the stage you might be in. Six questions. Take Where am I?
- Log it day by day in the tracker, with what came just before. It needs a free account. Open the tracker
Common questions
- Is DHEA the same as prasterone?
- Prasterone is DHEA. The Pakistan Menopause Society's recommendations list it as dehydroepiandrosterone (prasterone) among the hormones used in vaginal treatments, and NICE NG23 uses the name vaginal prasterone. (Source: Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026))
- Does DHEA help low libido?
- The British Menopause Society says that for oral DHEA, trials and meta-analyses have not definitively proven a benefit for sexual function in women with normal adrenal function, and that further research is needed before it can be recommended. (Source: British Menopause Society, Tool for Clinicians: Testosterone replacement in menopause (reviewed May 2026))
- Is DHEA a kind of HRT?
- NICE NG23 mentions DHEA only as vaginal prasterone, a treatment for genitourinary symptoms. Oral DHEA is sold in Pakistan, but the British Menopause Society says more research is needed before it can be recommended. (Source: NICE NG23, Menopause: identification and management (last updated 15 April 2026))
- Will DHEA help my bones?
- The Menopause Society, in its 2021 statement on osteoporosis, says there is no convincing evidence that DHEA improves bone density or lowers the risk of fractures after menopause. (Source: The Menopause Society (then The North American Menopause Society), Management of osteoporosis in postmenopausal women: the 2021 position statement, Menopause 2021;28(9):973-997)
Sources
- NICE NG23, Menopause: identification and management (last updated 15 April 2026)Section: 1.4.5; 1.5.5 to 1.5.10; 1.5.25 · Opened 1 October 2026© NICE 2026 Menopause: identification and management. Available from www.nice.org.uk/guidance/ng23 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
- British Menopause Society, Tool for Clinicians: Testosterone replacement in menopause (reviewed May 2026)Section: Oral DHEA; testosterone in the central nervous system · Opened 1 October 2026
- Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026)Section: 1.5.2; Table 1; 2.2; 5.5; Table 10 · Opened 1 October 2026
- British Menopause Society, Consensus statement: Genitourinary syndrome of menopause (GSM) (reviewed November 2025)Section: Treatment; Non-hormonal lubricants and moisturisers · Opened 10 October 2026
- The Menopause Society (then The North American Menopause Society), Management of osteoporosis in postmenopausal women: the 2021 position statement, Menopause 2021;28(9):973-997Section: Nutrition: other supplements · Opened 15 October 2026